Meeting
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
Authors
Tom Stinchcombe
Duke Cancer Institute, Durham, NC
Tom Stinchcombe , Bradley J. Monk , Alicia Frances Clare Okines , Paula R Pohlmann , Evan Y. Yu , Tanios S. Bekaii-Saab , Yoshiaki Nakamura , David M. O'Malley , Vicky Kang , Luke N. Walker , Martin Reck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04579380
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3151)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3151
Abstract #
TPS3151
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (SGNTUC-019).
First Author: Evan Y. Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
First Author: Matt D. Galsky
Poster
2021 Genitourinary Cancers Symposium
SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (trial in progress).
First Author: Evan Y. Yu
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
First Author: Fei Ma